Delayed HCV Treatment Claims Require Medical Evidence Linking the Delay to Injury

Case: Wallace Collier v. Woodrow Myers
Court: United States Court of Appeals for the Eleventh Circuit
Date: November 6, 2026
Disposition: Summary judgment affirmed.

Publication status: The opinion is designated “NOT FOR PUBLICATION.” It applies existing law rather than announcing a new binding circuit precedent.

1. Introduction

This decision concerns the evidence a prisoner must produce to establish that delayed medical treatment caused a constitutionally actionable injury. Wallace Gary Collier, a Florida prisoner proceeding without counsel, alleged that the refusal to provide direct acting antivirals, or DAAs, for his hepatitis C virus infection caused permanent liver damage. His lawsuit arose under 42 U.S.C. § 1983 and the Eighth Amendment’s prohibition against cruel and unusual punishment.

Collier sued Corizon Health, Inc., a private prison healthcare provider, and Woodrow A. Myers, a senior Corizon executive. He alleged that they maintained a policy of withholding HCV treatment to save money. Although both defendants obtained summary judgment, only the appeal against Myers remained for decision: Corizon’s intervening bankruptcy resulted in the extinguishment of the claims against it and dismissal of that portion of the appeal.

The appellate issue was narrow. The court did not decide whether HCV was a serious medical need or reconsider whether the challenged conduct amounted to deliberate indifference. Instead, it asked whether Collier had supplied sufficient medical evidence connecting the treatment delay during Corizon’s tenure to his later severe liver fibrosis.

The central holding: Evidence of severe fibrosis after a provider’s contract ended did not, without evidence connecting the condition to an injurious delay during that provider’s responsibility, establish causation.

2. Background and Procedural History

The alleged denial of treatment

Collier alleged that he contracted HCV in 2007 while incarcerated at Union Correctional Institution. Initially, he experienced tiredness and minor pain. He maintained that subsequent evaluations were inadequate and that he did not receive appropriate specialist assessment or testing for liver damage.

According to his complaint, DAAs became available in 2014. After learning about them independently in 2015, he repeatedly requested specialist care and treatment. He alleged that Corizon doctors reassured him about his liver enzyme levels, while one doctor told him in 2016 that the drugs were too expensive and Corizon was not funding them.

Collier’s account placed his fibrosis diagnosis around January 2018. The laboratory records he submitted contained an earlier, November 2017 report identifying an F3 fibrosis score, meaning severe liver scarring. He later received DAAs because of an injunction in separate litigation, but alleged that the treatment did not cure his fibrosis.

The defendants’ response

Although Collier initially alleged that Corizon provided care from 2015 through 2017, the relevant contractual period identified in the summary-judgment proceedings was September 2013 through May 2016. Myers denied personal involvement in Collier’s treatment and knowledge of his medical needs.

Corizon submitted a declaration from Dr. Craig Hutchinson explaining the drugs’ high anticipated cure rates and substantial expense—approximately $84,000 and $95,000. According to the declaration, efforts to secure legislative funding or obtain drugs from manufacturers in exchange for treatment data failed. Corizon and the Florida Department of Corrections consequently began collecting information to prioritize patients for treatment if funding became available. Collier was among the 5,376 HCV patients under Corizon’s care.

The district court’s ruling

A magistrate judge recommended denying summary judgment, but the district court did not adopt that recommendation. The district court found support for the existence of a policy withholding DAAs without state funding. Nevertheless, it concluded that Collier had not demonstrated resulting harm.

Using the treatment framework discussed in Hoffer v. Secretary, Florida Department of Corrections, the district court reasoned that treatment would have been indicated at fibrosis stage F2 or higher, or earlier with an exacerbating condition or signs of rapid progression. Crucially, the court assumed, without deciding, that this framework represented the constitutional minimum.

Because the record did not establish Collier’s fibrosis stage during Corizon’s contractual period, the district court concluded that he could not show his condition was worse because treatment had been withheld during that period.

3. Summary of the Opinion

The Eleventh Circuit affirmed summary judgment for Myers on the surviving appeal. Its principal conclusions were:

  • Causation remained an independent requirement. A serious medical need and deliberately indifferent conduct did not eliminate the need to prove resulting injury.
  • The November 2017 laboratory result did not supply the missing causal connection. It established severe fibrosis after Corizon’s contract ended, but did not show when the disease had reached a treatment-triggering stage.
  • A delay-based medical claim required verifying medical evidence. Collier had not produced sufficient evidence showing a detrimental effect attributable to the relevant delay.
  • Judicial notice could not substitute for that evidence. The court refused to accept expert testimony from separate litigation as true merely because it appeared in another case’s record.

The decision therefore rested on an evidentiary failure, not a determination that withholding effective treatment for financial reasons is constitutionally permissible.

4. Analysis

A. Precedents Cited and Their Role

The constitutional claim and its elements

Estelle v. Gamble, 429 U.S. 97, 104 (1976)

This foundational decision establishes that deliberate indifference to prisoners’ serious medical needs can violate the Eighth Amendment. It supplied the constitutional basis for Collier’s claim. The appellate court did not use it to resolve a disputed question about the seriousness of HCV or the defendants’ state of mind.

Wade v. United States, 13 F.4th 1217, 1225 (11th Cir. 2021)

The court relied on this decision for three distinct elements: an objectively serious medical need, deliberate indifference, and injury caused by the official’s wrongful conduct. Its importance was structural: proof concerning the first two elements could not compensate for insufficient proof of the third.

Hill v. Dekalb Reg'l Youth Det. Ctr., 40 F.3d 1176, 1188 (11th Cir. 1994)

This was the central causation authority. It requires an inmate alleging an unconstitutional delay in treatment to place “verifying medical evidence” in the record establishing the delay’s detrimental effect. The court applied that requirement to the gap between Collier’s later F3 diagnosis and the earlier period of Corizon’s responsibility.

Hope v. Pelzer, 536 U.S. 730 (2002)

The opinion identified this decision because it overruled Hill v. Dekalb Reg'l Youth Det. Ctr. in part on other grounds. The qualification matters: the panel continued to treat the medical-verification requirement as applicable, while acknowledging that not every aspect of the earlier decision remained intact.

The HCV treatment framework

Hoffer v. Secretary, Florida Department of Corrections, 973 F.3d 1263 (11th Cir. 2020)

Referred to as “Hoffer II,” this decision concerned a constitutionally adequate framework for treating Florida prisoners with HCV. The opinion also cites it under the abbreviated title Hoffer v. Sec'y, Fla. Dep't of Corr. when explaining fibrosis staging.

The framework provided DAAs to patients at F2 or above, while patients at F0 or F1 generally required an exacerbating condition or signs of rapid fibrosis progression. It supplied a reference point for identifying when earlier treatment might have been required. However, the district court expressly assumed rather than decided that the framework established the constitutional minimum. This appeal should not be read as making those treatment thresholds universally controlling in every HCV case.

Hoffer v. Jones, 290 F. Supp. 3d 1292 (N.D. Fla. 2017)

Referred to as “Hoffer I,” this separate class action supplied the expert testimony and exhibits Collier wanted the courts to judicially notice. It was not treated as establishing Collier’s individual medical history or causation. The district court did not expressly address his notice request; the appellate court expressly rejected the renewed request.

Summary judgment and the scope of appellate review

Grange Mut. Cas. Co. v. Slaughter, 958 F.3d 1050, 1056 (11th Cir. 2020)

This decision supplied de novo review of summary judgment, with the evidence viewed favorably to the nonmoving party. The appellate court therefore independently assessed whether Collier’s evidence could support a material factual dispute.

Garczynski v. Bradshaw, 573 F.3d 1158, 1165 (11th Cir. 2009)

The court cited this case for the proposition that a “mere scintilla” of evidence cannot defeat summary judgment. Although favorable inferences belonged to Collier, the court could not replace missing medical evidence with speculation about when his fibrosis developed.

United States v. Campbell, 26 F.4th 860, 873 (11th Cir. 2022) (en banc)

This decision supported the rule that issues omitted from an initial appellate brief are forfeited. The panel explained that the district court’s findings on the first two deliberate-indifference elements were unchallenged, leaving causation as the issue for decision.

Limits on judicial notice

United States v. Jones, 29 F.3d 1549, 1553 (11th Cir. 1994)

This case distinguishes recognizing another lawsuit and its filings from accepting the factual assertions in those filings as true. It directly supported rejection of Collier’s effort to establish causation through judicial notice of expert testimony from Hoffer I.

Grayson v. Warden, Comm'r, Ala. Dep't of Corr., 869 F.3d 1204, 1224–25 (11th Cir. 2017)

This decision reinforced that findings in one case cannot become conclusive in another simply through judicial notice. Together with Federal Rule of Evidence 201(b), it prevented the separate class-action record from automatically supplying disputed medical facts in Collier’s individual action.

B. Legal Reasoning

1. An objectionable policy and a compensable injury are separate questions

Collier’s principal allegation concerned a policy of withholding effective medication because funding was unavailable. But the existence of such a policy did not itself establish that the policy caused his fibrosis or made it worse. The constitutional claim required an individualized connection between the challenged conduct and his injury.

The court’s reasoning consequently separated two propositions: Collier had severe fibrosis, and the defendants’ treatment delay caused additional liver damage. The November 2017 report supported the first proposition. It did not, standing alone, establish the second.

2. The timing of medical deterioration was decisive

Corizon’s responsibility ended in May 2016, approximately eighteen months before the documented F3 result. The missing evidence concerned Collier’s condition during the earlier period: whether he had already reached a stage warranting treatment, had an exacerbating condition, or showed rapid progression.

The later result did not prove that fibrosis began only after Corizon left. Equally, it did not establish that treatment during Corizon’s tenure would have prevented the injury claimed. The court treated that uncertainty as a failure of proof, not as an affirmative finding that the delay was harmless.

3. The treatment framework requires careful reading

The opinion’s closing application contains awkward wording: it introduces “either” but joins its lettered alternatives with “and.” Earlier passages describe the framework more clearly—F2 or higher generally triggered treatment, while F0 or F1 could warrant treatment with an exacerbating condition or rapid progression.

Read as a whole, the opinion does not clearly establish that every patient must demonstrate both F2-level fibrosis and rapid progression. Its operative point is that Collier lacked medical evidence identifying a relevant treatment-triggering condition during Corizon’s tenure.

4. Judicial notice is not an evidentiary shortcut

Federal Rule of Evidence 201(b) permits judicial notice of facts not subject to reasonable dispute. A court may recognize that expert testimony was filed in another proceeding without accepting that testimony’s medical conclusions as indisputable facts.

The ruling does not make evidence originating in another lawsuit categorically unusable. It means that disputed medical propositions must reach the record through an appropriate evidentiary route, rather than acquiring conclusive status merely because another court received them.

5. The decision leaves important questions unresolved

The panel did not decide that cost alone excuses withholding DAAs, that Corizon’s policy was lawful, or that Myers could be liable merely because he held a supervisory position. Nor did it establish an inflexible requirement of expert testimony in every delayed-treatment case. It applied the requirement for verifying medical evidence to the particular evidentiary gap before it.

C. Potential Impact

Although nonbinding, the decision offers practical guidance for medical-care litigation:

  • Plaintiffs must develop a treatment-and-injury timeline. Records showing disease stage, progression, aggravating conditions, and treatment indications during the defendant’s responsibility may be critical.
  • A later diagnosis does not automatically establish earlier causation. Additional medical evidence may be needed to connect later damage to an earlier untreated period.
  • Policy evidence and individual injury evidence serve different purposes. Proof of a blanket treatment restriction does not necessarily prove the restriction injured a particular claimant.
  • Class-action relief does not resolve every individual damages claim. Systemwide evidence may inform the dispute, but individual causation remains a separate question.
  • Healthcare-provider transitions can make attribution especially important. The relevant evidence must connect harm to the period and conduct for which the particular defendant may be responsible.

The opinion also highlights a practical difficulty for prisoners whose earlier testing was allegedly inadequate: missing historical records may complicate proof of progression. The court nevertheless did not shift the causation burden or treat the alleged absence of adequate testing as a substitute for medical verification.

5. Complex Concepts Simplified

Deliberate indifference
A constitutional standard addressing a sufficiently culpable disregard of a prisoner’s serious medical needs—not simply an unfavorable treatment outcome.
Causation
The connection between the defendant’s wrongful conduct and the injury. Having a serious illness does not by itself establish that a particular treatment delay caused additional harm.
Verifying medical evidence
Medical evidence supporting the claim that waiting for treatment had a detrimental effect. Here, the missing link concerned the condition of Collier’s liver during the relevant treatment period.
Fibrosis staging
A scale describing liver scarring: F0 means none, F1 mild, F2 moderate, F3 severe, and F4 cirrhosis.
Summary judgment
A decision without trial when no genuine dispute of material fact requires resolution and the moving party is entitled to judgment as a matter of law.
De novo review
Independent appellate review of the legal ruling, rather than deference to the district court’s legal conclusion.
Judicial notice
Acceptance of an indisputable fact without ordinary proof. It does not ordinarily permit disputed testimony from another case to be accepted as true.

6. Conclusion

The Eleventh Circuit affirmed because Collier did not provide sufficient medical evidence linking his severe fibrosis to delayed treatment during Corizon’s period of responsibility. The decision reinforces that causation remains indispensable even when a serious medical need and deliberately indifferent conduct are not contested on appeal.

Its broader significance is evidentiary, not an endorsement of cost-based treatment restrictions: a delayed-treatment claim requires proof connecting the defendant’s conduct, the relevant timeframe, and the patient’s resulting harm.